Amylyx Pharmaceuticals (AMLX) Interest Coverage Ratio (2021 - 2026)

Amylyx Pharmaceuticals' Interest Coverage Ratio history runs 6 years deep, the most recent figure standing at 0.88 for Q1 2026.

• On a quarterly basis, Interest Coverage Ratio rose 92.84% year-over-year to 0.88 in Q1 2026; TTM through Mar 2026 was 3.2, a 95.73% increase from a year earlier, with the FY2025 full-year figure at 0.77, up 61.31% from the prior year.
• Interest Coverage Ratio retreated to 0.88 in Q1 2026 per AMLX's latest filing, from 0.85 in the prior quarter.
• Across five years, Interest Coverage Ratio topped out at 3.22 in Q4 2023 and bottomed at 265.8 in Q2 2024.
• The 5-year median for Interest Coverage Ratio is 0.85 (2025), against an average of 33.14.
• Across the five-year window, Interest Coverage Ratio jumped 205.44% in 2023 and plunged 1100636.82% in 2024, its largest moves.
• Year by year, Interest Coverage Ratio stood at 74.32 in 2022, then surged by 104.34% to 3.22 in 2023, then tumbled by 107.96% to 0.26 in 2024, then plunged by 232.24% to 0.85 in 2025, then fell by 3.31% to 0.88 in 2026.
• Per Business Quant, the three latest AMLX Interest Coverage Ratio figures stand at 0.88 (Q1 2026), 0.85 (Q4 2025), and 0.69 (Q3 2025).